These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 18173955)
1. Antiatherosclerotic effects of statins: LDL versus non-LDL effects. Selwyn AP Curr Atheroscler Rep; 2007 Oct; 9(4):281-5. PubMed ID: 18173955 [TBL] [Abstract][Full Text] [Related]
2. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
3. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins. Clearfield MB J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192 [TBL] [Abstract][Full Text] [Related]
4. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Sawada N; Liao JK Antioxid Redox Signal; 2014 Mar; 20(8):1251-67. PubMed ID: 23919640 [TBL] [Abstract][Full Text] [Related]
5. Potential vascular benefits of statins. Kinlay S Am J Med; 2005 Dec; 118 Suppl 12A():62-7. PubMed ID: 16356810 [TBL] [Abstract][Full Text] [Related]
7. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Liao JK Am J Cardiol; 2005 Sep; 96(5A):24F-33F. PubMed ID: 16126020 [TBL] [Abstract][Full Text] [Related]
8. Intensive statin therapy for Indians: Part-I. Benefits. Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339 [TBL] [Abstract][Full Text] [Related]
9. Lipid and non-lipid effects of statins. Paoletti R; Bolego C; Cignarella A Handb Exp Pharmacol; 2005; (170):365-88. PubMed ID: 16596807 [TBL] [Abstract][Full Text] [Related]
10. The evolving role of statins in the management of atherosclerosis. Vaughan CJ; Gotto AM; Basson CT J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252 [TBL] [Abstract][Full Text] [Related]
11. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen. McCarty MF Med Hypotheses; 2002 Sep; 59(3):268-79. PubMed ID: 12208152 [TBL] [Abstract][Full Text] [Related]
12. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583 [TBL] [Abstract][Full Text] [Related]
13. Inflammation and the development of atherosclerosis. Mizuno Y; Jacob RF; Mason RP J Atheroscler Thromb; 2011; 18(5):351-8. PubMed ID: 21427505 [TBL] [Abstract][Full Text] [Related]
14. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Auer J; Berent R Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380 [TBL] [Abstract][Full Text] [Related]
15. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Bruckert E; Ferrières J Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429 [TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
17. Moving beyond the "LDL hypothesis". Werner C; Laufs U Vasa; 2015 Sep; 44(5):333-40. PubMed ID: 26317252 [TBL] [Abstract][Full Text] [Related]